62,000 Shares in Tempest Therapeutics, Inc. (NASDAQ:TPST) Purchased by Fullcircle Wealth LLC

Fullcircle Wealth LLC purchased a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 3rd quarter, HoldingsChannel.com reports. The fund purchased 62,000 shares of the company’s stock, valued at approximately $87,000.

Separately, Dimensional Fund Advisors LP acquired a new position in shares of Tempest Therapeutics in the second quarter valued at approximately $55,000. Hedge funds and other institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Stock Performance

Shares of NASDAQ:TPST opened at $0.91 on Friday. Tempest Therapeutics, Inc. has a 12-month low of $0.88 and a 12-month high of $6.00. The company’s 50 day moving average price is $1.24 and its two-hundred day moving average price is $2.08. The firm has a market cap of $22.93 million, a PE ratio of -0.57 and a beta of -1.78. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12.

Tempest Therapeutics (NASDAQ:TPST) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.05. Equities research analysts predict that Tempest Therapeutics, Inc. will post -1.5 earnings per share for the current year.

Insider Buying and Selling

In other Tempest Therapeutics news, major shareholder Versant Venture Capital Vi, L. sold 400,000 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $1.35, for a total transaction of $540,000.00. Following the sale, the insider now directly owns 597,940 shares in the company, valued at $807,219. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 3.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $47.00 price target on shares of Tempest Therapeutics in a report on Thursday, October 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Tempest Therapeutics currently has an average rating of “Buy” and a consensus target price of $20.75.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.